Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure
Source: View publication →
In patients with reduced left ventricular ejection fraction and symptomatic congestive heart failure, the addition of enalapril to conventional therapy significantly reduced all-cause mortality and hospitalizations for heart failure.
Key Findings
Study Design
Study Limitations
Clinical Significance
The SOLVD Treatment trial provided definitive evidence that ACE inhibitors improve survival and reduce morbidity in symptomatic heart failure with reduced ejection fraction, establishing these agents as a cornerstone of heart failure management for decades.
Historical Context
Following the success of the CONSENSUS trial, which showed benefits of enalapril in severe (NYHA Class IV) heart failure, the SOLVD trial was designed to evaluate the mortality effects of ACE inhibition in a broader population of patients with mild to moderate chronic heart failure, fundamentally shifting the paradigm of heart failure treatment from symptom-only management to prognostic improvement.
Guided Discussion
High-yield insights from every perspective
What is the physiological mechanism by which Enalapril interrupts the 'vicious cycle' of neurohormonal activation in patients with reduced ejection fraction?
Key Response
In HFrEF, reduced cardiac output triggers the Renin-Angiotensin-Aldosterone System (RAAS) and Sympathetic Nervous System. While initially compensatory, chronic RAAS activation leads to increased afterload (via Angiotensin II-mediated vasoconstriction) and preload (via Aldosterone-mediated salt/water retention), alongside direct cardiotoxicity and remodeling. Enalapril, an ACE inhibitor, blocks the conversion of Angiotensin I to II, thereby reducing systemic vascular resistance and attenuating the progressive ventricular dilation that drives heart failure progression.
In a patient matching the SOLVD criteria, how should you manage a 25% increase in serum creatinine and a potassium of 5.1 mEq/L two weeks after initiating Enalapril?
Key Response
The SOLVD trial and subsequent clinical experience demonstrate that a mild rise in creatinine (up to 30% from baseline) is expected due to the loss of Angiotensin II-mediated efferent arteriolar vasoconstriction in the kidney. This usually reflects a functional rather than a structural change. Clinicians should generally continue the medication if the rise is <30% and potassium is <5.5 mEq/L, as the long-term mortality benefits established in SOLVD outweigh the transient hemodynamic drop in GFR.
Contrast the mortality outcomes of the SOLVD Treatment trial with the earlier CONSENSUS trial. How did the differences in NYHA classification between these cohorts influence the observed relative risk reduction?
Key Response
The CONSENSUS trial (1987) enrolled patients with NYHA Class IV (severe) heart failure and showed a 40% reduction in mortality. The SOLVD Treatment trial (1991) enrolled patients with milder symptoms (NYHA II-III) and showed a 16% reduction. This suggests that while ACE inhibitors are universally beneficial in HFrEF, the absolute and relative magnitude of effect on mortality is most pronounced in patients with the highest baseline risk and more advanced stages of cardiac dysfunction.
Given that the SOLVD trial was conducted before the routine use of beta-blockers, MRAs, and SGLT2 inhibitors, how should we value its legacy in the era of 'quadruple therapy' and the PARADIGM-HF results?
Key Response
SOLVD established the foundational role of RAS blockade. However, the PARADIGM-HF trial later demonstrated that Sacubitril/Valsartan (ARNI) was superior to Enalapril in reducing death and hospitalization. While SOLVD proved ACE inhibitors are life-saving compared to placebo/standard care (digoxin/diuretics), modern practice-changing evidence has shifted the 'gold standard' from ACE inhibitors to ARNIs as the first-line RAS antagonist in the foundational four pillars of HFrEF management.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The SOLVD trial utilized a 'run-in' period where patients were given the study drug briefly before randomization to assess tolerance. How does this design choice impact the internal versus external validity regarding adverse event rates like angioedema and cough?
Key Response
Run-in periods enhance internal validity by ensuring the randomized cohort can tolerate the medication, which minimizes drop-outs and increases statistical power to see a treatment effect. However, it compromises external validity (generalizability) because it underestimates the true incidence of adverse effects in a real-world population. Patients who developed early side effects during the run-in would never have been randomized, making the drug appear safer in the trial than it might be in unselected clinical practice.
As a reviewer in 1991, what concerns would you raise regarding the baseline medications and the exclusion of specific demographics in the SOLVD Treatment cohort?
Key Response
A critical reviewer would flag the low representation of women (approximately 20%) and the fact that beta-blockers—now a standard of care—were used in only a small fraction of patients (approx. 8%). Furthermore, the heavy reliance on digoxin and diuretics as the control arm 'background' therapy represents an outdated comparator by modern standards, though it was appropriate for the late 1980s. A reviewer would demand sub-group analyses to determine if the benefit remained consistent across genders and different levels of baseline renal function.
Based on the SOLVD Treatment and Prevention results, how should the strength of recommendation for ACE inhibitors vary between symptomatic HFrEF and asymptomatic LV dysfunction?
Key Response
The SOLVD Treatment trial provided Class I, Level A evidence for ACE inhibitors in symptomatic HFrEF (NYHA II-IV). The companion SOLVD Prevention trial demonstrated that ACE inhibitors also reduced the risk of developing symptomatic HF and HF hospitalizations in asymptomatic patients with LVEF ≤ 35%. Current guidelines (ACC/AHA/HFSA) reflect this by recommending RAS blockade for all patients with HFrEF regardless of symptoms to prevent remodeling, though they now prefer ARNIs (Class 1, Level A) over ACE inhibitors where feasible, based on subsequent head-to-head evidence.
Clinical Landscape
Noteworthy Related Trials
CONSENSUS Trial
Tested
Enalapril
Population
Patients with severe congestive heart failure
Comparator
Placebo
Endpoint
All-cause mortality
SAVE Trial
Tested
Captopril
Population
Patients with left ventricular dysfunction after myocardial infarction
Comparator
Placebo
Endpoint
All-cause mortality
CHARM-Alternative Trial
Tested
Candesartan
Population
Patients with heart failure and left ventricular systolic dysfunction intolerant to ACE inhibitors
Comparator
Placebo
Endpoint
Cardiovascular death or hospitalization for heart failure
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis